Treatment of diseases and disorders related to the activity of transducin beta-type protein 1 (TBL 1), including myeloproliferative neoplasia and chronic myeloid leukemia
A therapeutically effective amount of an agent that alters the interaction of TBL1 with a coactivating molecule for use in the treatment and / or prevention of myeloproliferative neoplasia or chronic myeloid leukemia, said agent having the formula: ** Formula ** or a pharmaceutically salt acceptable of it.Una cantidad terapéuticamente eficaz de un agente que altera la interacción de TBL1 con una molécula coactivadora para uso en el tratamiento y/o la prevención de neoplasia mieloproliferativa o leucemia mieloide crónica, teniendo dicho agente la fórmula:**Fórmula** o una sal farmacéuticamente aceptable del mismo.
